Anti-PPAR gamma antibody [3A4A9,1E6A1] (ab70405)

Overview

  • Product nameAnti-PPAR gamma antibody [3A4A9,1E6A1]See all PPAR gamma primary antibodies ...
  • Description
    Mouse monoclonal [3A4A9,1E6A1] to PPAR gamma
  • Tested applicationsWB, ELISA, Flow Cytmore details
  • Species reactivity
    Reacts with: Sheep, Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Chicken, Cow, Cat, Dog, Pig, Chimpanzee, Cynomolgus Monkey, Rhesus monkey, Chinese Hamster
  • Immunogen

    Recombinant fragment: KLIYDRCDLN CRIHKKSRNK CQYCRFQKCL AVGMSHNAIR FGRMPQAEKE KLLAEISSDI DQLNPESADL RALAKHLYDS YIKSFPLTKA KARAILTGKT T, corresponding to amino acids 170-270 of Human PPAR gamma with His tag expressed in E.coli strain BL21 (DE3)

  • Positive control
    • Truncated PPAR gamma-His recombinant protein. Full length PPAR gamma transfected CHO-K1 cell lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab70405 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/2000. Detects a band of approximately 75 kDa (predicted molecular weight: 58 kDa).
ELISA 1/10000.
Flow Cyt 1/100.

Target

  • FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
  • Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
  • Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
    Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
    Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
    Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
  • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CIMT1 antibody
    • GLM1 antibody
    • HUMPPARG antibody
    • NR1C3 antibody
    • Nuclear receptor subfamily 1 group C member 3 antibody
    • OTTHUMP00000185032 antibody
    • OTTHUMP00000185036 antibody
    • PAX8/PPARG Fusion Gene antibody
    • Peroxisome proliferator activated nuclear receptor gamma variant 1 antibody
    • Peroxisome proliferator activated receptor gamma 1 antibody
    • Peroxisome Proliferator Activated Receptor gamma antibody
    • Peroxisome proliferator-activated receptor gamma antibody
    • PPAR gamma antibody
    • PPAR-gamma antibody
    • PPARG antibody
    • PPARG_HUMAN antibody
    • PPARG1 antibody
    • PPARG2 antibody
    • PPARG3 antibody
    see all

Anti-PPAR gamma antibody [3A4A9,1E6A1] images

  • All lanes : Anti-PPAR gamma antibody [3A4A9,1E6A1] (ab70405) at 1/500 dilution

    Lane 1 : Molecular weight marker
    Lane 2 : Truncated PPAR gamma-His recombinant protein
    Lane 3 : Full length PPAR gamma transfected CHO-K1 cell lysate


    Predicted band size : 58 kDa
    Observed band size : 12,80 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 58 kDa. We are unsure as to the identity of these extra bands.
  • Overlay histogram showing HepG2 cells stained with ab70405 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab70405, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

References for Anti-PPAR gamma antibody [3A4A9,1E6A1] (ab70405)

ab70405 has not yet been referenced specifically in any publications.

Product Wall

Application Western blot
Loading amount 10 µg
Gel Running Conditions Reduced Denaturing (8 % Tris-Tricine-SDS-Page)
Sample Cow Tissue lysate - whole (subcutan fat)
Specification subcutan fat
Treatment 10 mM Hepes
Blocking step Roti-Block in TBS-T, 0,1 % as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 23°C
Username

Ms. Barbara Heitkönig

Verified customer

Submitted Oct 29 2013

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Sheep Cell lysate - whole cell (PAECs (pulmonary artery endothelial cells))
Loading amount 25 µg
Specification PAECs (pulmonary artery endothelial cells)
Gel Running Conditions Reduced Denaturing (10% gel)
Blocking step BSA as blocking agent for 45 minute(s) · Concentration: 3% · Temperature: 23°C
Username

Ms. Nancy Tseng

Verified customer

Submitted Sep 12 2012

Thank you for your reply.

For the phospho-specific antibody, ab60953,you should avoid milk. The protocol is below:

Cell Lysis and WB Protocol

Cell Lysis Protocol

1. For adherent cells, wash cells with Wash Buffer...

Read More

I am very pleased to hear you would like to accept our offer and test ab60953 andab70405 in sheep. These codes will give you: 1 free primary antibody each before the expiration date. To redeem this offer, please submit an Abreview for sheep and include...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"